Literature DB >> 22694310

Quantitative proteomic analysis of induced pluripotent stem cells derived from a human Huntington's disease patient.

Jung-Il Chae1, Dong-Wook Kim, Nayeon Lee, Young-Joo Jeon, Iksoo Jeon, Jihye Kwon, Jumi Kim, Yunjo Soh, Dong-Seok Lee, Kang Seok Seo, Nag-Jin Choi, Byoung Chul Park, Sung Hyun Kang, Joohyun Ryu, Seung-Hun Oh, Dong Ah Shin, Dong Ryul Lee, Jeong Tae Do, In-Hyun Park, George Q Daley, Jihwan Song.   

Abstract

HD (Huntington's disease) is a devastating neurodegenerative genetic disorder caused by abnormal expansion of CAG repeats in the HTT (huntingtin) gene. We have recently established two iPSC (induced pluripotent stem cell) lines derived from a HD patient carrying 72 CAG repeats (HD-iPSC). In order to understand the proteomic profiles of HD-iPSCs, we have performed comparative proteomic analysis among normal hESCs (human embryonic stem cells; H9), iPSCs (551-8) and HD-iPSCs at undifferentiated stages, and identified 26 up- and down-regulated proteins. Interestingly, these differentially expressed proteins are known to be involved in different biological processes, such as oxidative stress, programmed cell death and cellular oxygen-associated proteins. Among them, we found that oxidative stress-related proteins, such as SOD1 (superoxide dismutase 1) and Prx (peroxiredoxin) families are particularly affected in HD-iPSCs, implying that HD-iPSCs are highly susceptible to oxidative stress. We also found that BTF3 (basic transcription factor 3) is up-regulated in HD-iPSCs, which leads to the induction of ATM (ataxia telangiectasia mutated), followed by activation of the p53-mediated apoptotic pathway. In addition, we observed that the expression of cytoskeleton-associated proteins was significantly reduced in HD-iPSCs, implying that neuronal differentiation was also affected. Taken together, these results demonstrate that HD-iPSCs can provide a unique cellular disease model system to understand the pathogenesis and neurodegeneration mechanisms in HD, and the identified proteins from the present study may serve as potential targets for developing future HD therapeutics.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22694310     DOI: 10.1042/BJ20111495

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  42 in total

Review 1.  iPSC-based drug screening for Huntington's disease.

Authors:  Ningzhe Zhang; Barbara J Bailus; Karen L Ring; Lisa M Ellerby
Journal:  Brain Res       Date:  2015-09-30       Impact factor: 3.252

2.  Proceedings: cell therapies for Parkinson's disease from discovery to clinic.

Authors:  Rosa Canet-Aviles; Geoffrey P Lomax; Ellen G Feigal; Catherine Priest
Journal:  Stem Cells Transl Med       Date:  2014-08-22       Impact factor: 6.940

3.  RTP801 Is Involved in Mutant Huntingtin-Induced Cell Death.

Authors:  Núria Martín-Flores; Joan Romaní-Aumedes; Laura Rué; Mercè Canal; Phil Sanders; Marco Straccia; Nicholas D Allen; Jordi Alberch; Josep M Canals; Esther Pérez-Navarro; Cristina Malagelada
Journal:  Mol Neurobiol       Date:  2015-04-16       Impact factor: 5.590

Review 4.  Induced Pluripotent Stem Cells in Huntington's Disease: Disease Modeling and the Potential for Cell-Based Therapy.

Authors:  Ling Liu; Jin-Sha Huang; Chao Han; Guo-Xin Zhang; Xiao-Yun Xu; Yan Shen; Jie Li; Hai-Yang Jiang; Zhi-Cheng Lin; Nian Xiong; Tao Wang
Journal:  Mol Neurobiol       Date:  2015-12-10       Impact factor: 5.590

5.  Genotyping, generation and proteomic profiling of the first human autosomal dominant osteopetrosis type II-specific induced pluripotent stem cells.

Authors:  Minglin Ou; Chunhong Li; Donge Tang; Wen Xue; Yong Xu; Peng Zhu; Bo Li; Jiansheng Xie; Jiejing Chen; Weiguo Sui; Lianghong Yin; Yong Dai
Journal:  Stem Cell Res Ther       Date:  2019-08-14       Impact factor: 6.832

Review 6.  Using induced pluripotent stem cell neuronal models to study neurodegenerative diseases.

Authors:  Xinwen Zhang; Di Hu; Yutong Shang; Xin Qi
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2019-03-18       Impact factor: 5.187

7.  SRCP1 Conveys Resistance to Polyglutamine Aggregation.

Authors:  Stephanie Santarriaga; Holly N Haver; Adam J Kanack; Alicia S Fikejs; Samantha L Sison; John M Egner; Jonathan R Bostrom; Emily R Seminary; R Blake Hill; Brian A Link; Allison D Ebert; K Matthew Scaglione
Journal:  Mol Cell       Date:  2018-07-19       Impact factor: 17.970

Review 8.  DNA repair mechanisms in Huntington's disease.

Authors:  Ida Jonson; Rune Ougland; Elisabeth Larsen
Journal:  Mol Neurobiol       Date:  2013-01-30       Impact factor: 5.590

9.  A novel manganese-dependent ATM-p53 signaling pathway is selectively impaired in patient-based neuroprogenitor and murine striatal models of Huntington's disease.

Authors:  Andrew M Tidball; Miles R Bryan; Michael A Uhouse; Kevin K Kumar; Asad A Aboud; Jack E Feist; Kevin C Ess; M Diana Neely; Michael Aschner; Aaron B Bowman
Journal:  Hum Mol Genet       Date:  2014-12-08       Impact factor: 6.150

Review 10.  Modeling Huntington's disease with induced pluripotent stem cells.

Authors:  Julia A Kaye; Steven Finkbeiner
Journal:  Mol Cell Neurosci       Date:  2013-02-28       Impact factor: 4.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.